AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. - 10. (Cancelled)

11. (Currently amended) A method of providing topical analgesia to a subject comprising topically administering to peripheral sites in the subject a pharmaceutical composition comprising (i) synergistically effective amounts of morphine and butamben and (ii) a physiologically acceptable topical excipient, to potentiate analgesia at the peripheral sites, wherein morphine and butamben are present in a ratio of about 1:0.4.

12. – 16. (Cancelled)

17. (Previously Presented) The method according to claim 11, wherein the pharmaceutical composition contains morphine in a dose of about 0.1% to about 10% of the composition.

18. (Previously Presented) The method according to claim 11, wherein the pharmaceutical composition contains morphine in a dose of about 0.5% to about 5% of the composition.

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Previously Presented) The method according to claim 11, wherein the pharmaceutical composition contains butamben in a dose of about 0.5% to about 5% of the composition.

25. (Previously Presented) The method according to claim 11, wherein the pharmaceutical composition contains butamben in a dose of about 0.01% to about 1% of the composition.

26. (Previously Presented) The method according to claim 11, wherein the pharmaceutical composition contains butamben in a dose of about 0.01% to about 0.05% of the composition.

27. (Original) The method according to claim 11, wherein the pharmaceutical composition further comprises a tolerance attenuating or preventing NMDA receptor antagonist and wherein the NMDA receptor antagonist is selected from the group consisting of dextromethorphan, dextrorphan, ketamine, pyroloquinoline quinone, cis-4-(phosphonomethyl)-2-piperdine carboxylic acid, MK801, memantine, and their mixtures and pharmaceutically acceptable salts thereof.

28. (Previously Presented) The method according to claim 27, wherein the pharmaceutical composition contains the NMDA receptor antagonist in a dose of about 0.01% to about 25% of the composition.

29. (Previously Presented) The method according to claim 27, wherein the pharmaceutical composition contains the NMDA receptor antagonist in a dose of about 0.1% to about 15% of the composition.

30. (Previously Presented) The method according to claim 27, wherein the pharmaceutical composition contains the NMDA receptor antagonist in a dose of about 0.5% to about 5% of the composition.

31. (Previously Presented) The method according to claim 27, wherein the pharmaceutical composition contains the NMDA receptor antagonist in a dose of about 0.01% to about 1% of the composition.

32. (Previously Presented) The method according to claim 27, wherein the pharmaceutical composition contains the NMDA receptor antagonist in a dose of about 0.01% to about 0.05% of the composition.

33. (Previously Presented) The method according to claim 11, wherein topical administration of the pharmaceutical composition is provided to cutaneous, mucosal, vaginal, rectal, ocular, or nasal surfaces.

34. (Original) The method according to claim 11, wherein the pharmaceutical composition is topically administered to a subject in an amount and duration sufficient to prevent or relieve acute and chronic peripheral neuropathy.

35. (Cancelled)